Evidence Hub

734-P: Prevalence of Low and Borderline Levels of Vitamin B12 in Type 2 Diabetic Patients Treated with Metformin: A Cross-Sectional Study in Argentina

Cinthia Cela, Mariana Langus

2020

190 participants · 1 citation

Abstract

Background: Vitamin B12 deficiency, a common cause of megaloblastic anemia, has been associated with cognitive decline and increasing risk of depression. Metformin therapy has been associated with vitamin B12 (B12) deficiency in several populations. However, information regarding this adverse effect in Argentina populations is limited. The aim of this study was to examine the relation between metformin use and B12 status in individuals with type 2 diabetes mellitus (T2DM) in Argentina. Design and Setting: Cross-sectional study at a public university hospital. Results: At present 190 patients were included (See Table 1). Serum vitamin B12 levels were low ( Conclusions and Future Directions: Our study showed low or borderline levels of vitamin B12 in 14.7.3% and 25.26 % of patients, respectively. This large number of patients with low o borderline levels of B12 suggests that a high proportion of patients may be at risk of B12 deficiency related conditions. Close monitoring of B12 level, and measurement of other biomarkers of cellular B12 deficiency may help to identify these patients at risk. Disclosure C. Cela: None. M. Langus: None.

How strong is the evidence?

Evidence Hub reads this as a cross-sectional, done in people. Its evidence level is 4 of 5 (Low · observational). Observational designs can show an association but not prove cause. Reported size: 190 participants or records.

How the five levels of evidence work. The level is assigned automatically from the abstract and can be wrong, so check the paper.

Read the paper

Related studies

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free